Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Successful completion of U.S. phase I study of liposomal annamycin in AML

Feb. 4, 2020

Different drivers can turn the wheel in glioblastoma's vicious cycle

Feb. 4, 2020

Corvus offers new data from ongoing phase I/Ib trial of CPI-818 in advanced T-cell lymphomas

Feb. 3, 2020

Eisai initiates phase II study of E-7090 in advanced cholangiocarcinoma with FGFR2 gene fusion

Feb. 3, 2020

DB-020 prevents cisplatin-induced hearing loss in animal model, enters clinical trial

Feb. 3, 2020

Eli Lilly and Company presents SERD inducers for cancer

Feb. 3, 2020

GlaxoSmithKline discloses CREB2 inhibitors

Feb. 3, 2020

Voronoi patents new protein kinase inhibitors

Feb. 3, 2020

Exelixis presents phase Ib data for XL-888 plus pembrolizumab in advanced gastrointestinal cancer

Feb. 3, 2020

Preclinical data lead to clinical study of in derazantinib in advanced gastric cancer

Feb. 3, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...